Dr. Neal Shore Presents TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients

/in /by

LUGPA CME Program- Program Chair: Neal D. Shore, MD | T Replacement Therapy and T Suppression Strategies: How to Optimize T Management for both the Hypogonadal and the Prostate Cancer Patient

/in /by

November 5, Chicago, open to members and non-members of LUGPA

Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl

/in /by

Upfront Chemotherapy in Prostate Cancer

/in /by